Free Trial

Uniphar (LON:UPR) Reaches New 52-Week High - Still a Buy?

Uniphar logo with Medical background

Key Points

  • Uniphar plc shares reached a new 52-week high of GBX 350 ($4.72) during trading, reflecting strong market interest.
  • Brokerages maintain a mixed outlook on Uniphar with Shore Capital issuing a "buy" rating and a target price of GBX 375, while Deutsche Bank issued a "hold" rating.
  • The company operates in the healthcare sector, serving over 200 pharmaceutical and medical technology manufacturers with a market capitalization of £1.07 billion.
  • Need better tools to track Uniphar? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Uniphar plc (LON:UPR - Get Free Report) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as GBX 350 ($4.72) and last traded at GBX 349.05 ($4.71), with a volume of 11034 shares changing hands. The stock had previously closed at GBX 338.50 ($4.56).

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on UPR. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a GBX 375 target price on shares of Uniphar in a research report on Wednesday, July 30th. Shore Capital reiterated a "buy" rating on shares of Uniphar in a research report on Thursday, May 29th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of GBX 375.

Check Out Our Latest Report on Uniphar

Uniphar Stock Up 1.9%

The company has a current ratio of 0.90, a quick ratio of 0.60 and a debt-to-equity ratio of 119.48. The company has a market capitalization of £1.07 billion, a price-to-earnings ratio of 23.99 and a beta of 0.75. The firm's fifty day simple moving average is GBX 330.07 and its two-hundred day simple moving average is GBX 276.30.

About Uniphar

(Get Free Report)

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Uniphar Right Now?

Before you consider Uniphar, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Uniphar wasn't on the list.

While Uniphar currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid
NVIDIA Earnings: All Signs Point to More Growth Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines